PMID- 28162244
OWN - NLM
STAT- MEDLINE
DCOM- 20170727
LR  - 20170727
IS  - 0040-5957 (Print)
IS  - 0040-5957 (Linking)
VI  - 72
IP  - 2
DP  - 2017 Apr
TI  - Pharmacogenetics of hypersensitivity drug reactions.
PG  - 231-243
LID - S0040-5957(16)31285-9 [pii]
LID - 10.1016/j.therap.2016.12.009 [doi]
AB  - Adverse drug reactions are a significant cause of morbidity and mortality and 
      represent a major burden on the healthcare system. Some of those reactions are 
      immunologically mediated (hypersensitivity reactions) and can be clinically 
      subdivided into two categories: immediate reactions (IgE-related) and delayed 
      reactions (T-cell-mediated). Delayed hypersensitivity reactions include both 
      systemic syndromes and organ-specific toxicities and can be triggered by a wide 
      range of chemically diverse drugs. Recent studies have demonstrated a strong 
      genetic association between human leukocyte antigen alleles and susceptibility to 
      delayed drug hypersensitivity. Most notable examples include human leukocyte 
      antigen (HLA)-B*57:01 allele and abacavir hypersensitivity syndrome or 
      HLA-B*15:02 and HLA-B*58:01 alleles related to severe cutaneous reactions induced 
      by carbamazepine and allopurinol, respectively. This review aims to explore our 
      current understanding in the field of pharmacogenomics of HLA-associated drug 
      hypersensitivities and its translation into clinical practice for predicting 
      adverse drug reactions.
CI  - Copyright (c) 2017 Societe francaise de pharmacologie et de therapeutique. 
      Published by Elsevier Masson SAS. All rights reserved.
FAU - Negrini, Simone
AU  - Negrini S
AD  - Department of internal medicine, clinical immunology unit, centre of excellence 
      for biomedical research, university of Genoa, 16132 Genoa, Italy. Electronic 
      address: negrini@unige.it.
FAU - Becquemont, Laurent
AU  - Becquemont L
AD  - Pharmacology department, faculty of medicine Paris-Sud, UMR 1184, CEA, DSV/iMETI, 
      division of immuno-virology, IDMIT, Inserm center for immunology of viral 
      infections and autoimmune diseases, hopital Bicetre, university Paris Sud, 
      Assistance publique-Hopitaux de Paris, 94275 Le Kremlin-Bicetre, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170103
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
RN  - 0 (Anticonvulsants)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (HLA Antigens)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - 33CM23913M (Carbamazepine)
RN  - 63CZ7GJN5I (Allopurinol)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Allopurinol/adverse effects
MH  - Anticonvulsants/adverse effects
MH  - Carbamazepine/adverse effects
MH  - Dideoxynucleosides/adverse effects
MH  - Drug Hypersensitivity/*genetics/immunology
MH  - Enzyme Inhibitors/adverse effects
MH  - *Genetic Predisposition to Disease
MH  - HLA Antigens/*genetics/immunology
MH  - Humans
MH  - Pharmacogenetics
MH  - Reverse Transcriptase Inhibitors/adverse effects
OTO - NOTNLM
OT  - Abacavir
OT  - Allopurinol
OT  - Carbamazepine
OT  - HLA
OT  - Hypersensitivity drug reactions
EDAT- 2017/02/07 06:00
MHDA- 2017/07/28 06:00
CRDT- 2017/02/07 06:00
PHST- 2016/07/05 00:00 [received]
PHST- 2016/09/02 00:00 [accepted]
PHST- 2017/02/07 06:00 [pubmed]
PHST- 2017/07/28 06:00 [medline]
PHST- 2017/02/07 06:00 [entrez]
AID - S0040-5957(16)31285-9 [pii]
AID - 10.1016/j.therap.2016.12.009 [doi]
PST - ppublish
SO  - Therapie. 2017 Apr;72(2):231-243. doi: 10.1016/j.therap.2016.12.009. Epub 2017 
      Jan 3.